"Leprosy elimination: World Health Organization". Archived from the original on 2014-03-14. Retrieved 2019-07-03


Download 28.27 Kb.
Sana02.01.2022
Hajmi28.27 Kb.
#202054
Bog'liq
№2 Бабажон Адаб.


xdxvvv

  1. "Leprosy elimination: World Health Organization". Archived from the original on 2014-03-14. Retrieved 2019-07-03.

  2. "Leprosy new case detection rates, 2016". WHO. WHO. Retrieved 19 December 2019.

  3. "WHO | MDT and drug resistance". WHO. Retrieved 2019-07-22.

  4. "WHO | WHO donated MDT". WHO. Retrieved 2019-07-23.

  5. "World Health Organization- Weekly Epidemiological Record. Geographical distribution of new leprosy cases, 2016".

  6. Balagon M, Saunderson P, Gelber R (2011). Does clofazimine prevent erythema nodosum leprosum (ENL) in leprosy? A retrospec􀆟 ve study, comparing the experience of mul􀆟 bacillary pa􀆟 ents receiving either 12 or 24 months WHO-MDT. Lep Rev. 82: 213–221.

  7. Becx-Bleumink M, Berhe D, Mannetje W. The management of nerve damage in the leprosy control services (Editorial). Lepr Rev (1990) 61, 1-11

  8. Bri􀆩 on W. The management of leprosy reversal reac􀆟 ons (Editorial). Lepr Rev, 1998; 69: 225-234.

  9. Chandler D, Hansen K, Mahato B et al. Household Costs of Leprosy Reac􀆟 ons (ENL) in Rural India. PLo SNTDs 2015.

  10. Costa, Perpétua do Socorro Silva, Fraga et al. Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condi􀆟 on.

  11. Cro􀅌 R, Nicholls P, Richardus J et al. Incidence rates of acute nerve func􀆟 on impairment in leprosy: aprospec􀆟 ve cohort analysis a􀅌 er 24 months (The Bangladesh Acute Nerve Damage Study). Lepr Rev, 2000; 71: 18-33.

  12. Cro􀅌 R, Nicholls P, Steyerberg E et al. 2000. A clinical predic􀆟 on rule for nerve-func􀆟 on impairment in leprosy pa􀆟 ents. Lancet 355(9215): 1603–1606.

  13. Darlong J, Govindharaj P, Charles D et al. Experiences with Thalidomide for Erythema Nodosum Leprosum. Lepr Rev. 2016 Jun; 87(2):211-20.

  14. Duthie MS, Gillis TP, Reed SG (November 2011). "Advances and hurdles on the way toward a leprosy vaccine". Hum Vaccin. 7 (11): 1172–83. doi:10.4161/hv.7.11.16848. PMC 3323495. PMID 22048122.

  15. Eichelmann, K.; González González, S. E.; Salas-Alanis, J. C.; Ocampo-Candiani, J. (2013-09-01). "Leprosy. An Update: Definition, Pathogenesis, Classification, Diagnosis, and Treatment". Actas Dermo-Sifiliográficas (English Edition). 104(7): 554–563. doi:10.1016/j.adengl.2012.03.028. ISSN 1578-2190. PMID 23870850.

  16. Elias J Jr, Nogueira-Barbosa M, Feltrin L et al. 2009. Role of ulnar nerve sonography in leprosy neuropathy with electrophysiologic correla􀆟 on. J Ultrasound Med. 28(9):1201–1209.NEJM 2006;355(7):739.

  17. Finnerup N et al. Pharmacotherapy for neuropathic pain in adults: a systema􀆟 c review and meta-analysis.The Lancet Neurology. 2015. 14(2): p. 162-173.

  18. Grzybowski, Andrzej; Nita, Małgorzata (2016-01-01). "Leprosy in the Bible". Clinics in Dermatology. 34 (1): 3–7. doi:10.1016/j.clindermatol.2015.10.003. ISSN 0738-081X. PMID 26773616.

  19. Haroun O et al. Inves􀆟 ga􀆟 on of neuropathic pain in treated leprosy pa􀆟 ents in Ethiopia: a cross-sec􀆟 onal tudy. Pain. 2012. 153(8): p. 1620-4.

  20. Hatemi G, Mahr A, Ishigatsubo Y et al. Trial of apremilast for oral ulcers in Behçet’s syndrome. NEJM. 2019; 381: 1918-28. DOI: 10.1056/NEJMoa1816594

  21. Hossain D. Using methotrexate to treat pa􀆟 ents with ENL unresponsive to steroids and clofazimine: a eport on 9 pa􀆟 ents. Lep Rev. 2013;84(1):105-12.

  22. ILEP (2002). Learning Guide Two: How to recognize and manage leprosy reac􀆟 ons. www.leprosyinforma􀆟 on.org

  23. Jain S, Visser L, Praveen T et al. 2009. High-resolu􀆟 on sonography: a new technique to detect nerve damage in leprosy. PLoS Negl Trop Dis. 3(8):e498.

  24. Job, C. K.; Drain, V.; Truman, R.; Deming, A. T.; Sanchez, R. M.; Hastings, R. C. (2016-06-01). "The pathogenesis of leprosy in the nine-banded armadillo and the significance of IgM antibodies to PGL-1". Indian Journal of Leprosy. 64 (2): 137–151. ISSN 0254-9395. PMID 1607712.

  25. Jump up to:a b c "WHO | Global leprosy update, 2015: time for action, accountability and inclusion". WHO. Retrieved 2019-01-14.

  26. Kahawita I, Lockwood D. Towards understanding the pathology of erythema nodosum leprosum. Transac􀆟 ons of The Royal Society of Tropical Medicine and Hygiene, Volume 102, Issue 4, April 2008, Pages 329–337, h􀆩 ps://doi.org/10.1016/j.trstmh.2008.01.004

  27. Kaur I, Dogra S, Narang T et al. Compara􀆟 ve effi cacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: a randomized study. Australas J Dermatol. 2009;50(3):181-5.

  28. Kumar B, Dogra S. Leprosy: A disease with diagnos􀆟 c and management challenges! Indian J Dermatol Venereol Leprol 2009; 75:111-5.

  29. Kumar, Bhushan; Uprety, Shraddha; Dogra, Sunil (2016-02-11). "Clinical Diagnosis of Leprosy". International Textbook of Leprosy. Retrieved 2019-02-12.

  30. Lambert S, Alembo D, Nigusse S et al. A Randomized Controlled Double Blind Trial of Cyclosporin versus Prednisolone in the Management of Leprosy Pa􀆟 ents with New Type 1 Reac􀆟 on, in Ethiopia. PLoS Negl Trop Dis. 2016; 10(4): e0004502.

  31. Lockwood D, Bryceson A (2003) The return of thalidomide: new uses and renewed concerns—reply. Lep Rev. 74: 290–294.

  32. Lockwood D, Vinayakumar S, Stanley JN, McAdam KP, Colston MJ. Clinical features and outcome of reversal (type 1) reac􀆟 ons in Hyderabad, India. Int J Lepr Other Mycobact Dis. 1993; 61(1):8-15.

  33. Lockwood DNJ, Darlong J, Govindharaj P, Kurian R, Sundarrao P, John A. AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reac􀆟 ons in India: Main fi ndings. PLoS Negl Trop Dis. 2017; 11(3): e0005348.

  34. Maggie Veatch (21 Feb 2019). "Leprosy still lurks in United States, study says". CNN.

  35. Maghanoy A, Balagon M, Saunderson P et al. A prospec􀆟 ve randomised, double-blind, placebo controlled trial on the eff ect of extended clofazimine on Erythema Nodosum Leprosum (ENL) in mul􀆟 bacillary (MB) leprosy. Lep Rev. 2017;88(2):208-16.

  36. Mahmoud M, Walker S. A Systema􀆟 c Review of Adverse Drug Reac􀆟 ons associated with Thalidomide in the treatment of Erythema Nodosum Leprosum. Lepr Rev (2019) 90, 142-160.

  37. Merle CS, Cunha SS, Rodrigues LC (2010). "BCG vaccination and leprosy protection: Review of current evidence and status of BCG in leprosy control". Expert Review of Vaccines. 9 (2): 209–222. doi:10.1586/ERV.09.161. PMID 20109030.

  38. Moschella, Samuel L; Garcia-Albea, Victoria (September 2016). "International Textbook of Leprosy" (PDF). Differential Diagnosis of Leprosy. p. 3, Section 2.3. Retrieved July 4, 2019.

  39. Naafs B. Treatment dura􀆟 on of reversal reac􀆟 on: A reappraisal, Back to the past. Lepr Rev. 2003; 74:328-36.

  40. Nabarro L, Aggarwal D, Armstrong M et al. The use of steroids and thalidomide in the management of Erythema Nodosum Leprosum; 17 years at the Hospital for Tropical Diseases, London. Lep Rev. 2016; 87:221-31.

  41. Negera E et al. Clinico-pathological features of erythema nodosum leprosum: A case-control study at ALERT hospital, Ethiopia. PLoS NTD 2017

  42. Pocaterra L, Jain S, Reddy R et al. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg. 2006;74(5):868-79.

  43. Rambukkana A, Zanazzi G et al. Contact-dependent demyelina􀆟 on by Mycobacterium leprae in the absence of immune cells. Science, 2002 296: 927-931. DOI: 10.1126/science.1067631

  44. Rao P, Sugamaran D, Richard J et al. Mul􀆟 -centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reac􀆟 ons in leprosy. Lepr Rev. 2006; 77: 25–33.

  45. Reibel, F.; Cambau, E.; Aubry, A. (2015-09-01). "Update on the epidemiology, diagnosis, and treatment of leprosy". Médecine et Maladies Infectieuses. 45 (9): 383–393. doi:10.1016/j.medmal.2015.09.002. ISSN 0399-077X. PMID 26428602.

  46. Richardus J et al. Treatment with cor􀆟 costeroids of long-standing nerve func􀆟 on impairment in leprosy: a randomized controlled trial (TRIPOD 3). Lepr Rev. 2003. 74(4): p. 311-8.

  47. Ridley D.S., Jopling W.H. Classification of leprosy according to immunity. A five-group system // Int. J. Lepr. – 1966. – Vol.34. – P. 255-273.

  48. Ridley DS, Jopling WH; Jopling (1966). "Classification of leprosy according to immunity. A five-group system". Int. J. Lepr. Other Mycobact. Dis. 34 (3): 255–73. PMID 5950347

  49. Rose P, Waters M. Reversal reac􀆟 ons in leprosy and their management (Editorial). Lepr Rev, 1991; 62:113-121.

  50. Santos J, Vendramini D, Nery J et al. Etanercept in erythema nodosum leprosum. Anais Brasileiros de Dermatologia. 2017;92(4):575-7.

  51. Saunderson P, Gebre S, Desta K et al. The pa􀆩 ern of leprosy-related neuropathy in the AMFES pa􀆟 ents in Ethiopia: defi ni􀆟 ons, incidence, risk factors and outcome. Lepr Rev. 2000 Sep;71(3):285-308.

  52. Schreuder P. The occurrence of reac􀆟 ons and impairments i n leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1978- 1995. III. Neural and other impairments. Int J Lepr, 1 998; 66: 170-181.

  53. Sehgal V, Koranne R, Sehgal S et al. 1985. Correla􀆟 on of morphological, bacteriological, histopathological and immunological feature of leprosy. A double-blind study. J Dermatol. 12(3):243–250.

  54. Setia MS, Steinmaus C, Ho CS, Rutherford GW (March 2006). "The role of BCG in prevention of leprosy: a meta-analysis". Lancet Infect Dis. 6 (3): 162–70. doi:10.1016/S1473-3099(06)70412-1. PMID 16500597.

  55. Sheskin J. Thalidomide in the Treatment of Lepra Reac􀆟 ons. Clin Pharm Ther. 1965; 6:303-6.

  56. Singh, Kunwar Sahab; Pandey, Bam Deo (March 2012). "Leprosy—Hidden Disease?". Science Reporter. 49 (3).

  57. Smith W, Nicholls P, Das L et al. 2009. Predic􀆟 ng neuropathy and reac􀆟 ons in leprosy at diagnosis and before incident events—results from the INFIR cohort study. PLoS Negl Trop Dis. 3(8):e500.

  58. Svein Atle Skålevåg. "Daniel Cornelius Danielssen". Store norske leksikon. Archived from the original on January 13, 2017. Retrieved January 1, 2017.

  59. Tatipally, Sushma; Srikantam, Aparna; Kasetty, Sanjay (2018-10-01). "Polymerase Chain Reaction (PCR) as a Potential Point of Care Laboratory Test for Leprosy Diagnosis—A Systematic Review". Tropical Medicine and Infectious Disease. 3 (4): 107. doi:10.3390/tropicalmed3040107. ISSN 2414-6366. PMC 6306935. PMID 30275432.

  60. Thangaraju P, Durai V, Showkath A. The role of etanercept in refractory erythema nodosum leprosum. Int J Mycobacteriol. 2016

  61. Toh H-S et al. Diagnosis and impact of neuropathic pain in leprosy pa􀆟 ents in Nepal a􀅌 er comple􀆟 on of mul􀆟 drug therapy. PLoS Negl Trop Dis. 2018. 12(7): p. e0006610.

  62. Van Brakel W, Nicholls P, Das L et al. 2005. The INFIR Cohort Study: inves􀆟 ga􀆟 ng predic􀆟 on, detec􀆟 on and pathogenesis of neuropathy and reac􀆟 ons in leprosy. Methods and baseline results of a cohort of mul􀆟 bacillary leprosy pa􀆟 ents in north India. Lepr Rev. 76(1):14–34.

  63. Van Brakel W. 2000. Peripheral neuropathy in leprosy and its consequences. Lepr Rev 71(Suppl):S146-153.

  64. Van Veen N et al. Decompressive surgery for trea􀆟 ng nerve damage in leprosy. A Cochrane review. Lepr Rev. 2009; 80(1):3-12.

  65. Van Veen N, Nicholls P, Smith W et al. Cor􀆟 costeroids for trea􀆟 ng nerve damage in leprosy. Lepr Rev 2008 79(4): 361-371

  66. Wagenaar I, Brandsma W, Post E et al. Normal threshold values for a monofi lament sensory test in sural and radial cutaneous nerves in Indian and Nepali volunteers. Lepr Rev 2014 85, 275-287.

  67. Wagenaar I, Post E, Brandsma W et al. Eff ec􀆟 veness of 32 versus 20 weeks of prednisolone in leprosy pa􀆟 ents with recent nerve func􀆟 on impairment: A randomized controlled trial. PLoS Negl Trop Dis. 2017 Oct;11(10):e0005952

  68. Walker S, Balagon M, Darlong J et al. ENLIST 1: An Interna􀆟 onal Mul􀆟 centre Cross-sec􀆟 onal Study of the Clinical Features of Erythema Nodosum Leprosum. PLoS Negl Trop Dis. 2015;9(9):e0004065.

  69. Walker S, Nicholls P, Dhakal S et al. A Phase Two randomized controlled double-blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous normal saline and oral prednisolone in individuals with leprosy Type 1 reac􀆟 ons and/or nerve func􀆟 on impairment. PloS NTDs 2011 doi.org/10.1371/journal.pntd.0001041

  70. WHO Expert Commi􀆩 ee on Leprosy. Seventh Report. Technical Report Series 874. Geneva: World Health Organiza􀆟 on; 1998.

  71. WHO, 2001. Interna􀆟 onal Classifi ca􀆟 on of Func􀆟 oning, Disability and Health. Geneva.

  72. World Health Organization (June 2018). "BCG vaccine: WHO position paper, February 2018 – Recommendations". Vaccine. 36 (24): 3408–3410. doi:10.1016/j.vaccine.2018.03.009. ISSN 0264-410X. PMID 29609965.

  73. Zeldis J, Williams B, Thomas S et al. S.T.E.P.S.: A comprehensive program for controlling and monitoring access to thalidomide. Clin Ther, 1999; 21: 319-330.

Download 28.27 Kb.

Do'stlaringiz bilan baham:



Ma'lumotlar bazasi mualliflik huquqi bilan himoyalangan ©fayllar.org 2024
ma'muriyatiga murojaat qiling